Olivier Tabary has been a researcher at Inserm at Inem since 2025. He began focusing on cystic fibrosis projects in 1996. Following his PhD in Reims and a post-doctoral fellowship at EMBL in Heidelberg, Germany, he spent a significant period at St Antoine Research Hospital in Paris. Throughout his career, he has advanced various techniques in microscopy, molecular and cell therapy, infection, and inflammation, consistently related to CF patient needs. In 2023, Dr. Tabary founded the startup Anoat Therapeutics to create a novel therapeutic approach for patients.

Seminar topic: ANO1 a new approach for cystic fibrosis; from basic science to translational studies